NM  Vol.2 No.4 , December 2011
Effects of L-Dopa and Dopamine D2 Agonists on Recollection and Familiarity in Idiopathic Nondementing Parkinson’s Disease
ABSTRACT
Idiopathic nondementing Parkinson’s disease (PD) is marked by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area. Recent brain imaging work implicates these structures in dopamine modulated networks subserving episodic memory. These findings are of relevance to PD because they suggest that dopamine depletion contributes to the disease-dependent decline in episodic memory, and therefore, this decline should, at least partially, be remediated by dopaminergic medication. Recognition memory (RM), recollection and familiarity during recognition was examined in 17 PD patients, 12 of whom were medicated with a D2 dopamine agonist (pramipexole or ropinirole) and l-dopa, with a further 5 PD control patients on l-dopa but no D2 agonist. Memory was tested “ON” and, following a period of medication withdrawal, “OFF” and compared to a group of 14 matched healthy volunteers (HV). The HVs were also tested twice in the absence of medication. The patients on the agonists PD showed significant impairments in recollection ON- and OFF-medication, whereas the l-dopa control patients exhibited a decline in OFF-recollection only. RM and familiarity were spared in both groups ON- and OFF-medication. These findings suggest that D2 dopamine agonists (combined with l-dopa) contribute to disease-dependent episodic memory impairment.

Cite this paper
nullN. Edelstyn, T. Shepherd, A. Mayes, S. Sherman and S. Ellis, "Effects of L-Dopa and Dopamine D2 Agonists on Recollection and Familiarity in Idiopathic Nondementing Parkinson’s Disease," Neuroscience and Medicine, Vol. 2 No. 4, 2011, pp. 318-329. doi: 10.4236/nm.2011.24042.
References
[1]   N. M. J. Edelstyn, T. S. Shepherd, A. R. Mayes, S. M. Sherman and S. J. Ellis, “Effect of Disease Severity and Dopaminergic Medication on Recollection and Familiarity in Patients with Idiopathic Nondementing Parkinson’s,” Neuropsychologia, Vol. 48, No. 5, 2010, pp. 1367-1375. doi:10.1016/j.neuropsychologia.2009.12.039

[2]   J. F. Hay, M. Moscovitch and B. Levine, “Dissociating Habit and Recollection: Evidence from Parkinson’s Disease, Amnesia and Focal Lesion Patients,” Neuropsychologia, Vol. 40, No. 8, 2002, pp. 1324-1334. doi:10.1016/S0028-3932(01)00214-7

[3]   N. M. J. Edelstyn, A. R. Mayes, L. Condon, M. Tunnicliffe and S. J. Ellis, “Recognition, Recollection, Familiarity and Executive Function in Patients with Moderate Parkinson’s Disease,” Journal of Neuropsychology, Vol. 1, No. 2, 2007, pp. 131-147. doi:10.1348/174866407X182565

[4]   J. Barnes, L. Boubert, J. Harris, A. J. Lees and A.S. David, “Reality Monitoring and Visual Hallucinations in Parkinson’s Disease,” Neuropsychologia, Vol. 41, No. 5, 2003, pp. 565-574. doi:10.1016/S0028-3932(02)00182-3

[5]   K. R. McDonald, A. R. Crossman, A. R. Mayes, J. P. R. Dick, M. W. Kellett and E. Poliakoff, “Recollection and Familiarity in Parkinson’s Disease,” Personal Communication.

[6]   P. S. R. Davidson, D. Anaki, J. A. Saint-Cyr, T. W. Chow and M. Moscovitch, “Exploring the Recognition Memory Deficit in Parkinson’s Disease: Estimates of Recollection versus Familiarity,” Brain, Vol. 129, No. 7, 2006, pp. 1768-1779. doi:10.1093/brain/awl115

[7]   B. Weiermann, M. A. Stephan, A. Kaelin-Lang and B. Meier, “Is There a Recognition Memory Deficit in Parkinson’s Disease: Evidence from Estimates of Recollection and Familiarity,” International Journal of Neuroscience, Vol. 120, No. 3, 2010, pp. 211-216. doi:10.3109/00207450903506510

[8]   M. Cohn, M. Moscovitch and P. S. R. Davidson, “Double Dissociation between Familiarity and Recollection in Parkinson’s Disease as a Function of Encoding Tasks,” Neuropsychologia, Vol. 48, No. 14, 2010, pp. 4142-4147. doi:10.1016/j.neuropsychologia.2010.10.013

[9]   A. P. Yonelinas, “The Nature of Recollection and Familiarity: A Review of 30 Years of Research,” Journal of Memory and Language, Vol. 46, No. 3, 2002, pp. 441-517. doi:10.1006/jmla.2002.2864

[10]   J. P. Aggleton and M. W. Brown, “Episodic Memory, Amnesia, and the Hippocampal-Anterior Thalamic Axis,” Behavioural Brain Sciences, Vol. 122, 1999, pp. 425-489. doi:10.1017/S0140525X99002034

[11]   J. P. Aggleton, J. R. Dumont and E. C. Warburton, “Unraveling the Contributions of the Diencephalon to Recognition Memory: A Review,” Learning and Memory, Vol. 18, 2011, pp. 384-400. doi:10.1101/lm.2167511

[12]   N. A. Otmakhova and J. E. Lisman, “D1/D5 Dopamine Receptor Activation Increases the Magnitude of Early Long-Term Potentiation at CA1 Hippocampal Synapses,” Journal of Neuroscience, Vol. 16, No. 23, 1996, pp. 7478-7486.

[13]   B. G. Mockett, W. M. Brooks, W. P. Tate and W. C. Abraham, “Dopamine D1/D5 Receptor Activation Fails to Initiate an Activity-Independent Late-Phase LTP in Rat Hippocampus,” Brain Research, Vol. 1021, No. 1, 2004, pp. 92-100. doi:10.1016/j.brainres.2004.06.039

[14]   M. A. Wood, M. P. Kaplan, A. Park, E. J. Oliveira, T. L. Lombardi and T. Abel, “Transgenic Mice Expressing a Truncated form of CREB-Binding Protein (CBP) Exhibit Deficits in Hippocampal Synaptic Plasticity and Memory Storage,” Learning and Memory, Vol. 13, 2006, pp. 609- 617. doi:10.1101/lm.86605

[15]   N. Lemon and D. Manahan-Vaughan, “Dopamine D1/D5 Receptors Gate the Acquisition of Novel Information through Hippocampus Long-Term Potentiation and Long-Term Depression,” Journal of Neuroscience, Vol. 26, No. 29, 2006, pp. 7723-7729. doi:10.1523/JNEUROSCI.1454-06.2006

[16]   D. M. Cummings, A. J. Milnerwood, G. M. Dallérac, V. Waights, J. Y. Brown, S. C. Vatsavayai, C. Hirst and K. P. S. J. Murphy, “Abberant Cortical Synaptic Plasticity and Dopaminergic Dysfunction in a Mouse Model of Huntinsdon’s Disease,” Human Molecular Genetics, Vol. 15, No. 19, 2006, pp. 2856-2868. doi:10.1093/hmg/ddl224

[17]   S. W. S. MacDonald, S. Cervenka, L. Farde, L. Nyberg and L. Backman, “Extrastriatal Dopamine D2 Receptor Binding Modulates Intraindividual Variability in Episodic Recognition and Executive Functioning,” Neuropsychologia, Vol. 47, No. 11, 2009, pp. 2299-2304. doi:10.1016/j.neuropsychologia.2009.01.016

[18]   S. Li, W. K. Cullen, R. Anwyl and M. J. Rowan, “Dopamine-Dependent Facilitation of LTP Induction in Hippocampal CA1 by Exposure to Spatial Novelty,” Nature Neuroscience, Vol. 6, No. 5, 2003, pp. 526-531. doi:10.1038/nn1049

[19]   M. Bentivoglio and M. Morelli, “Dopamine Circuits and Receptors,” In: S. B. Dunnett, M. Bentivoglio, A. Bjorklund and T. Hokfelt, Eds., Handbook of Chemical Neuroanatomy, Vol. 21, Dopamine, Chapter 1, Elsevier, 2005.

[20]   C. M. O’Carroll, S. J. Martin, J. Sandin, B. Frenguelli and R. G. M. Morris, “Dopaminergic Modulation of the Persistence of One-Trial Hippocampus-Dependent Memory,” Learning and Memory, Vol. 13, No. 6, 2006, pp. 760-769. doi:10.1101/lm.321006

[21]   B. G. Mockett, D. Guévremont, J. M. Williams and W.C. Abraham, “Dopamine D1/D5 Receptor Activation Reverses NMDA Receptor-Dependent Long-Term Depression in Rat Hippocampus,” Journal of Neuroscience, Vol. 27, No. 11, 2007, pp. 2918-2926. doi:10.1523/JNEUROSCI.0116-07.2007

[22]   U. Frey, H. Schroeder and H. Matthies, “Dopaminergic Antagonists Prevent Long-Term Maintenance of Posttetanic LTP in the CA1 Region of Rat Hippocampal Slices,” Brain Research, Vol. 522, No. 1, 1990, pp. 69-75. doi:10.1016/0006-8993(90)91578-5

[23]   U. Frey, H. Matthies and K. G. Reymann, “The Effect of Dopaminergic D1 Receptor Blockade during Tetanization on the Expression of Long-Term Potentiation in the Rat CA1 Region in Vitro,” Neuroscience Letters, Vol. 129, No. 1, 1991, pp. 111-114. doi:10.1016/0304-3940(92)90364-D

[24]   R. Bernabeu, L. Bevilaqua, P. Ardenghi, E. Bromberg, P. Schmitz, M. Bianchin, I. Izquierdo and J. H. Medina, “Involvement of Hippocampal cAMP/cAMP-Dependent Protein Kinase Signaling Pathways in a Late Memory Consolidation Phase of aversively Motivated Learning in Rats,” Proceedings of the National Academy of Science (USA), Vol. 94, 1997, pp. 7041-7046. doi:10.1073/pnas.94.13.7041

[25]   W. Schultz, “Predictive Reward Signal of Dopamine Neurons,” Journal of Neurophysiology, Vol. 80, No. 1, 1998, pp. 1-27.

[26]   J. E. Lisman and A. A. Grace, “The Hippocampal-VTA Loop: Controlling the Entry of Information into Long- Term Memory,” Neuron, Vol. 46, No. 5, 2005, pp. 703- 713. doi:10.1016/j.neuron.2005.05.002

[27]   N. Kemppainen, M. Laine, M. P. Laakso, V. Kaasinen, V. Nagren, T. Vahlber, T. Kurki and J. O. Rinne, “Hippocampal Dopamine D2 Receptors Correlate with Memory Functions in Alheimer’s Disease,” European Journal of Neuroscience, Vol. 19, 2003, pp. 149-154. doi:10.1046/j.1460-9568.2003.02716.x

[28]   A. A. Grace, “Phasic versus Tonic Dopamine Release and the Modulation of Dopamine System Responsivity: A Hypothesis for the Eitiology of Schizophrenia,” Neuroscience, Vol. 41, 1991, pp. 1-24. doi:10.1016/0306-4522(91)90196-U

[29]   A. A. Grace, S. B. Floresco, Y. Goto and D. J. Lodge, “Regulation of Firing of Dopaminergicneurons and Control of Goal-Directed Behaviors,” Trends in Neuroscience, Vol. 30, No. 5, 2007, pp. 220-227. doi:10.1016/j.tins.2007.03.003

[30]   J. C. Horvitz, “Mesolimbocortical and Nigrostriatal Dopamine Responses to Salient Non-Reward Events,” Neuroscience, Vol. 96, No. 4, 2000, pp. 651-656. doi:10.1016/S0306-4522(00)00019-1

[31]   W. Schultz, P. Dayan and R. R. Montague, “A Neural Substrate of Prediction and Reward,” Science, Vol. 275, No. 5306, 1997, pp. 1593-1599. doi:10.1126/science.275.5306.1593

[32]   W. Schultz, “Getting Formal with Dopamine and Reward,” Neuron, Vol. 36, No. 2, 2002, pp. 241-263. doi:10.1016/S0896-6273(02)00967-4

[33]   H. Umegaki, J. Munoz, R. C. Meyer, E. L. Spangler, J. Yoshimura, H. Ikari, A. Iguchi and D. K. Ingram, “Involvement of Dopamine D2 Receptors in Complex Maze Learning and Acetylcholine Release in Ventral Hippocampus of Rats,” Neuroscience, Vol. 103, No. 1, 2001, pp. 27-33. doi:10.1016/S0306-4522(00)00542-X

[34]   I. Bethus, D. Tse and R. G. M. Morris, “Dopamine and Memory: Modulation of the Persistence of Memory for Novel Hippocampal NMDA Receptor-Dependent Paired Associated,” Journal of Neuroscience, Vol. 30, No. 5, 2010, pp. 1610-1618. doi:10.1523/JNEUROSCI.2721-09.2010

[35]   M. G. Packard and N. M. White, “Memory Facilitation Produced by Dopamine Agonists: Role of Receptor Subtype and Mnemonic Requirements,” Pharmacology, Biochemistry and Behaviour, Vol. 33, 1989, pp. 511-518. doi:10.1016/0091-3057(89)90378-X

[36]   A. Marighetto, S. Valerio, N. Philippin, V. Bertaina- Anglade, C. Drieu La Rochelle, R. Jaffard and P. Morain, “Comparative Effects of the Dopaminergic Agonists Piribedil and Bromocriptine in Three Difference Paradigms in Rodents,” Journal of Pharmacology, Vol. 22, 2008, pp. 511-521. doi:10.1177/0269881107083836

[37]   A. I. Hersi, W. Rowe, P. Gaudreau and R. Quirion, “Dopamine D1 Receptor Ligands Modulate Cognitive Performance and Hippocampal Acetylcholine Release in Memory-Impaired Aged Rats,” Neuroscience, Vol. 69, 1996, pp. 1067-1074. doi:10.1016/0306-4522(95)00319-E

[38]   A. Floel, C. Breitenstein, F. Hummel, P. Celnik, C. Gingert, L. Sawaki, S. Knecht and L. G. Cohen, “Dopa-minergic Influences on Formation on a Motor Memory,” Annals of Neurology, Vol. 58, No. 1, 2005, pp. 121-130. doi:10.1002/ana.20536

[39]   S. Knecht, C. Breitenstein, S. Bushuven, S. Wailke, S. Kamping, A. Floel, A. Zwitselood and E. Berd Ringelstein, “Levodopa: Faster and Better Word Learning in Normal Humans,” Annals of Neurology, Vol. 56, 2005, pp. 20-26. doi:10.1002/ana.20125

[40]   A. Floel, G. Garraux, B. Xu, C. Breitenstein, S. Knecht, P. Herscovitch and L. G. Cohen, “Levodopa Increases Memory Encoding and Dopamine Release in the Striatum in the Elderly,” Neurobiology of Aging, Vol. 29, No. 2, 2008, pp. 267-279. doi:10.1016/j.neurobiolaging.2006.10.009

[41]   K. W. Lange, T. W. Robbins, C. D. Marsden, M. James, A. M. Owen and G. M Paul, “L-Dopa Withdrawal in Parkinson’s Disease Selectively Impairs Cognitive Performance in Tests Sensitive to Frontal Lobe Dysfunction,” Psychopharmacology, Vol. 107, No. 2-3, 1992, pp. 394- 404. doi:10.1007/BF02245167

[42]   S. J. G. Lewis, R. Cools, T. W. Robbins, A. Dove, R. A> Barker and A. M. Owen, “Using Executive Heterogeneity to Explore the Nature of Working Memory Deficits in Parkinson’s Disease,” Neuropsychologia, Vol. 41, No. 6, 2003, pp. 645-654. doi:10.1016/S0028-3932(02)00257-9

[43]   A. Costa, A. Peppe, G. Dell’Agnello, G. A. Carlesimo, L. Murri and U. Bonuccelli, “Dopaminergic Modulation of Visuospatial Working Memory in Parkinson’s Disease,” Dementia and Geriatric Cognitive Disorders, Vol. 15, No. 2, 2003, pp. 55-66. doi:10.1159/000067968

[44]   N. Fournet, O. Moreaud, J. L. Roulin, B. Naegele and J. Pellat, “Working Memory Functioning in Medicated Parkinson’s Disease Patients and the Effect of Withdrawal of Dopaminergic Medication,” Neuropsychology, Vol. 14, No. 2, 2000, pp. 247-253. doi:10.1037/0894-4105.14.2.247

[45]   C. Malapani, B. Rakitin, W. H. Meck, B. Deweer, B. Dubois and J. Gibbon, “Coupled Temporal Memories in Parkinson’s Disease: A Dopamine-Related Dysfunction,” Journal of Cognitive Neuroscience, Vol. 10, 1998, pp. 316-331. doi:10.1162/089892998562762

[46]   R. Cools, R. A. Barker, B. J. Sahakian and T. W. Robbins, “Enhanced or Impaired Cognitive Function in Parkinson’s Disease as a Function of Dopaminergic Medication and Task Demands,” Cerebral Cortex, Vol. 11, No. 2, 2001, pp. 1136-1143. doi:10.1093/cercor/11.12.1136

[47]   R. Cools, R. A. Barker, B. J. Sahakian and T. W. Robbins, “L-Dopa Medication Remediates Cognitive Flexibility, but Increases Impulsivity in Patients with Parkinson’s Disease,” Neuropsychologia, Vol. 41, No. 11, 2003, pp. 1431-1441. doi:10.1093/cercor/11.12.1136

[48]   A.E. Hayes, M. C. Davidson and S.W. Keele, “Towards a Functional Analysis of the Basal Ganglia,” Journal of Cognitive Neuroscience, Vol. 1, 1998, pp. 178-198. doi:10.1162/089892998562645

[49]   D. Shohamy, C. E. Myers, K. D. Geghman, J. Sage and M. A. Gluck, “L-Dopa Impairs Learning, But Spared Generalisation, in Parkinson’s Disease,” Neuropsychologia, Vol. 44, No. 5, 2006, pp. 774-784. doi:10.1016/j.neuropsychologia.2005.07.013

[50]   A. M. Gotham, R. G. Brown and C. D. Marsden, “Frontal Cognitive Function in Patients with Parkinson’s Disease ‘ON’ and ‘OFF’ Levodopa,” Brain, Vol. 111, No. 2, 1988, pp. 299-321. doi:10.1093/brain/111.2.299

[51]   V. Czernecki, B. Pillon, J. L. Houeto, J. B. Pochon, R. Levy and B. Dubois, “Motivation, Reward and Parkinson’s Disease: Influence of Dopatherapy,” Neuropsychologia, Vol. 40, No. 13, 2002, pp. 2257-2267. doi:10.1016/S0028-3932(02)00108-2

[52]   J. Kulisevsky, A. Avila, M. Barbano, R. Antonijoan, M. Berthier and A. Gironell, “Acute Effects of Levodopa on Neuropsychological Performance in Stable and Fluctuating Parkinson’s Disease Patients at Different Levodopa Plasma Levels,” Brain, Vol. 119, 1996, pp. 2121-2132. doi:10.1093/brain/119.6.2121

[53]   R. Cools, L. Altamirano and M. D’Esposito, “Reversal Learning in Parkinson’s Disease Depends on Medication Status and Outcome Valence,” Neuropsychologia, Vol. 44, No. 10, 2006, pp. 1663-1673. doi:10.1016/j.neuropsychologia.2006.03.030

[54]   J. B. Rowe, L. Hughes, B. C. P. Ghosh, D. Eckstein, C. H. Williams-Gray, S. Fallon, R. A. Barker and A. M. Owen, “Parkinson’s Disease and dopaminergic Therapy: Differential Effects on Movement, Reward and Cognition,” Brain, Vol. 131, No. 8, 2008, pp. 2094-2105. doi:10.1093/brain/awn112

[55]   J. A. Cooper, H. J. Sagar, S. M. Doherty, N. Jordan, P. Tidswell and E. V. Sullivan, “Different Effects of Dopa-minergic and Anticholinergics Therapies on Cognitive and Motor Function in Parkinson’s Disease,” Brain, Vol. 115, No. 6, 1992, pp. 1701-1725. doi:10.1093/brain/115.6.1701

[56]   E. Driver-Dunckley, J. Samanta and M. Stacy, “Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson’s Disease,” Neurology, Vol. 61, No. 3, 2003, pp. 422-423. doi:10.1212/01.WNL.0000076478.45005.EC

[57]   D. L. Dodd, K. J. Klos, J. H. Bower, Y. E. Geda, K. A. Josephs and J. E. Ahlskog, “Pathological Gambling Caused by Drugs Used to Treat Parkinson’s Disease,” Archives of Neurology, Vol. 62, No. 9, 2005, pp. 1377- 1381. doi:10.1001/archneur.62.9.noc50009

[58]   A. Costa, A. Peppe, G. Dell’Agnello, C. Caltagirone and G. A. Carlesimo, “Dopamine and Cognitive Functioning in De Novo Subjects with Parkinson’s Disease: Effects of Pramipexole and Pergolide on Working Memory,” Neuropsychologia, Vol. 47, No. 5, 2009, pp. 1374-1381. doi:10.1016/j.neuropsychologia.2009.01.039

[59]   M. M Hoehn and M. D. Yahr, “Parkinsonism: Onset, Progression and Mortality,” Neurology, Vol. 17, No. 5, 1967, pp. 427-442.

[60]   H. E. Nelson and J. Willison, “National Adult Reading Test,” Windsor, Berks, NFER-Nelson, 1991.

[61]   M. F. Folstein, S. E. Folstein and P. R. McHugh, “Mini-Mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician,” Journal of Psychiatric Research, Vol. 12, No. 3, 1975, pp. 189-198. doi:10.1016/0022-3956(75)90026-6

[62]   M. Roth, F. A. Huppert, C. Q. Mountjoy and E. Tym, “CAMDEX-R: The Cambridge Examination for Mental Disorders of the Elderly—Revised,” Cambridge University Press, Cambridge, 1998.

[63]   W. M. Reynolds and K. A. Kobak, “Hamilton Depression Inventory: A Self-Report Version of the Hamilton Depression Rating Scale,” Psychological Assessment Resources, Odessa, 1995.

[64]   S. Fahn and R. L. Elton, “The Unified Parkinson’s Disease Rating Scale,” In: S. Fahn, C. D. Marsden, D. B. Calne and M. Goldstein, Eds., Recent developments in Parkinson’s disease, Macmillan, Florham Park, 1987, pp. 293-304.

[65]   M. Coltheart, “The MRC Psycholinguistic Database,” Quarterly Journal of Experimental Psychology, Vol. 33A, 1981, pp. 497-505.

[66]   R. H. Baayen, R. Piepenbrock and H. van Rijn, “The CELEX Lexical Database (CD-ROM),” Linguistic Data Consortium, University of Pennsylvania, Philadelphia, 1993.

[67]   J. G. Snodgrass and J. Corwin, “Pragmatics of Measuring Recognition Memory. Applications to Dementia and Amnesia,” Quarterly Journal of Experimental Psychology, Vol. 117, No. 1, 1988, pp. 34-50. doi:10.1037/0096-3445.117.1.34

[68]   A. P. Yonelinas and L. L. Jacoby, “The Relation between Remembering and Knowing as Bases for Recognition: Effects of Size Congruency,” Journal of Memory and Language, Vol. 34, No. 5, 1995, pp. 622-643. doi:10.1006/jmla.1995.1028

[69]   S. J. Lewis, T. Foltynie, A. D. Blackwell, T. W. Robbins, A. M. Owen and R. A. Barker, “Heterogeneity of Parkinson’s Disease in the Early Clinical Stages Using a Data Driven Approach,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 76, No. 3, 2005, pp. 343-348. doi:10.1136/jnnp.2003.033530

[70]   M. Selikova, D. R. Williams, P.A. Kempster, J. L. Holton, T. Revesz and A. J. Lees, “A Clinic-Pathological Study of Subtypes in Parkinson’s Disease,” Brain, Vol. 132, No. 11, 2009, pp. 2947-2957. doi:10.1093/brain/awp234

[71]   R. A. Hauser, L. Gauger, W. M. Anderson and T. A. Zesiewicz, “Pramipexole-Induced Somnolence and Episodes of Daytime Sleep,” Movement Disorders, Vol. 15, No. 4, 2000, pp. 658-663. doi:10.1002/1531-8257(200007)

[72]   W. Ondo, R. Fayle, F. Atassi and J. Jankovic, “Modafinil for Daytime Somnolence in Parkinson’s Disease: Double Blind, Placebo Controlled Parallel Trial,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 76, No. 12, 2005, pp. 1636-1639. doi:10.1136/jnnp.2005.065870

[73]   D. M. Barch, “Pharmacological Manipulation of Human Working Memory,” Psychopharmacology (Berl), Vol. 174, No. 1, 2004, pp. 126-135. doi:10.1007/s00213-003-1732-3

[74]   J. D. E. Gabrieli, J. Singh, G. T. Stebbins and C. G. Goetz, “Reduced Working Memory Span in Parkinson’s Disease: Evidence for the Role of a Frontostriatal System in Working and Strategic Memory,” Neuropsychology, Vol. 10, No. 3, 1996, pp. 322-332. doi:10.1037/0894-4105.10.3.321

[75]   J. H. Meador-Woodruff, S. P. Damask and S. J. Watson Jr. “Differential Expression of Autoreceptors in the Ascending Dopamine Systems of the Human Brain,” Proceedings of the National Academy Science (USA), Vol. 91, 1994, pp. 8297-8301. doi:10.1073/pnas.91.17.8297

[76]   M. Matsumoto, K. Hidaka, S. Tada, Y. Tasaki and T. Yamaguchi, “Full-Length cDNA Cloning and Distribution of Human Dopamine D4 Receptor,” Molecular Brain Research, Vol. 29, No. 1, 1995, pp. 157-162. doi:10.1016/0169-328X(94)00245-A

[77]   L. Mrzljak, C. Bergson, M. Pappy, R. Huff, R. Levenson and P. S. Goldman-Rakic, “Localization of Dopamine D4 Receptors in GABAergic Neurons of the Primate Brain,” Nature (Lond), Vol. 381, 1996, pp. 245-248. doi:10.1038/381245a0

[78]   H. Takahashi, M. Kato, M. Hayashi, Y. Okubo, A. Takano, H. Ito and T. Suhara, “Memory and Frontal Lobe Functions: Possible Relations with Dopamine D2 Receptors in the Hippocampus,” NeuroImage, Vol. 34, No. 4, 2007, pp. 1643-1649. doi:10.1016/j.neuroimage.2006.11.008

[79]   E. Mohr, G. Fabbrini, J. Williams, J. Schlegel, C. Cox, P. Fedio and T. N. Chase, “Dopamine and Memory Function in Parkinson’s Disease,” Movement Disorders, Vol. 4, 2004, pp. 113-120. doi:10.1002/mds.870040202

[80]   S. Righi, M. P. Viggiano, M. Paganini, S. Ramat and P. Marini, “Recognition of Category-Related Visual Stimuli in Parkinson’s Disease: Before and after Pharmacological Treatment,” Neuropsychologia, Vol. 45, No. 13, 2007, 2931-2941. doi:10.1016/j.neuropsychologia.2007.06.002

 
 
Top